{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:43Z","timestamp":1791489703799,"version":"4.3.4"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UpToDate"},{"name":"WebMD"},{"name":"Medscape"},{"name":"AHK"},{"name":"Prime CME"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Methapharm"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Equillium"},{"name":"Knopp"},{"name":"Theravance"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaip.2019.11.024","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T13:18:39Z","timestamp":1574947119000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Eosinophilic Asthma"],"prefix":"10.1016","volume":"8","author":[{"given":"Ryan K.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parameswaran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Akuthota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.11.024_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","article-title":"The global burden of asthma: executive summary of the GINA Dissemination Committee report","volume":"59","author":"Masoli","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.11.024_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"52","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.024_bib3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2012.01.039","article-title":"Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma","volume":"129","author":"Ivanova","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(06)69290-8","article-title":"Asthma: defining of the persistent adult phenotypes","volume":"368","author":"Wenzel","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.024_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jaci.2010.11.015","article-title":"Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health\/National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"127","author":"Fitzpatrick","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.jaci.2016.08.048","article-title":"U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics","volume":"139","author":"Lefaudeux","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"L\u00f6tvall","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1164\/rccm.201107-1317PP","article-title":"Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program","volume":"185","author":"Jarjour","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(58)91385-0","article-title":"Treatment of chronic asthma with prednisolone: significance of eosinophils in the sputum","volume":"2","author":"Brown","year":"1958","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.024_bib12","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib14","doi-asserted-by":"crossref","first-page":"1602135","DOI":"10.1183\/13993003.02135-2016","article-title":"T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED","volume":"49","author":"Kuo","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.024_bib15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaci.2012.01.059","article-title":"Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines","volume":"129","author":"Bossley","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaci.2010.01.048","article-title":"The molecular phenotype of severe asthma in children","volume":"125","author":"Fitzpatrick","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0037-1606217","article-title":"Airway inflammation and inflammatory biomarkers","volume":"39","author":"Lim","year":"2018","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/ped.2018.0886","article-title":"Asthma endotyping and biomarkers in childhood asthma","volume":"31","author":"Licari","year":"2018","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jaip.2019.11.024_bib19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","article-title":"Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis","volume":"73","author":"Petsky","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2019.11.024_bib20","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.anai.2017.09.058","article-title":"Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma","volume":"119","author":"Blaiss","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib22","first-page":"CD011440","article-title":"Exhaled nitric oxide levels to guide treatment for adults with asthma","volume":"2016","author":"Petsky","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2019.11.024_bib23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib24","doi-asserted-by":"crossref","first-page":"1800938","DOI":"10.1183\/13993003.00938-2018","article-title":"\u201cT2-high\u201d in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin","volume":"53","author":"Pavlidis","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.024_bib25","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1513\/AnnalsATS.201309-307AW","article-title":"Clinical heterogeneity in the Severe Asthma Research Program","volume":"10","author":"Moore","year":"2013","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2019.11.024_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaip.2017.05.015","article-title":"Severe asthma phenotypes\u2014how should they guide evaluation and treatment?","volume":"5","author":"Fitzpatrick","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jaci.2014.02.006","article-title":"Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications","volume":"133","author":"Howrylak","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2016.06.061","article-title":"Asthma phenotypes in inner-city children","volume":"138","author":"Zoratti","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaip.2017.04.031","article-title":"Severe asthma in children","volume":"5","author":"Ramratnam","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.jaci.2016.06.060","article-title":"Pathways through which asthma risk factors contribute to asthma severity in inner-city children","volume":"138","author":"Liu","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib31","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cell.2010.03.004","article-title":"Asthma and allergic inflammation","volume":"140","author":"Locksley","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2019.11.024_bib32","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jaci.2013.11.042","article-title":"Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data","volume":"133","author":"Wu","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib33","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jaci.2009.06.029","article-title":"Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study","volume":"124","author":"van Veen","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib34","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1164\/ajrccm.164.5.2011026","article-title":"Factors associated with persistent airflow limitation in severe asthma","volume":"164","author":"ten Brinke","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib36","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib37","doi-asserted-by":"crossref","first-page":"00100","DOI":"10.1183\/23120541.00100-2015","article-title":"Clinical profile of patients with adult-onset eosinophilic asthma","volume":"2","author":"de Groot","year":"2016","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaip.2019.11.024_bib38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jaci.2014.02.015","article-title":"Innate lymphoid cells and asthma","volume":"133","author":"Yu","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaci.2015.05.037","article-title":"Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia","volume":"137","author":"Smith","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/014556130708600715","article-title":"The prevalence of Samter\u2019s triad in patients undergoing functional sinus surgery","volume":"86","author":"Kim","year":"2007","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.jaip.2019.11.024_bib42","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S1081-1206(10)61323-3","article-title":"Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease","volume":"94","author":"Mascia","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaip.2016.03.004","article-title":"Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity","volume":"4","author":"Divekar","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib44","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaip.2017.07.001","article-title":"Diagnostic accuracy of urinary LTE4 measurement to predict aspirin-exacerbated respiratory disease in patients with asthma","volume":"6","author":"Bochenek","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib45","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12931-018-0909-6","article-title":"The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease","volume":"19","author":"Comhair","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.11.024_bib46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJMcibr1514013","article-title":"Aspirin-exacerbated respiratory disease\u2014new prime suspects","volume":"374","author":"Laidlaw","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4168\/aair.2019.11.3.320","article-title":"Which factors associated with activated eosinophils contribute to the pathogenesis of aspirin-exacerbated respiratory disease?","volume":"11","author":"Choi","year":"2019","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2019.11.024_bib48","doi-asserted-by":"crossref","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.024_bib49","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib50","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib51","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib52","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.024_bib54","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib55","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib56","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A\u00a0study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib57","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib58","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib59","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaip.2019.11.024_bib61","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/cea.12695","article-title":"Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma","volume":"46","author":"Sehmi","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.11.024_bib62","first-page":"A7084","article-title":"High failure rate of anti-IL-5 therapies in prednisone-dependent asthma is associated with airway autoimmune responses [abstract]","volume":"199","author":"Mukherjee","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13223-016-0174-5","article-title":"Airway autoimmune responses in severe eosinophilic asthma following low-dose mepolizumab therapy","volume":"13","author":"Mukherjee","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fimmu.2017.00242","article-title":"Reslizumab and eosinophilic asthma: one step closer to precision medicine?","volume":"8","author":"Varricchi","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib66","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.11.024_bib67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaip.2019.09.036","article-title":"Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma","volume":"8","author":"Nair","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib70","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.11.024_bib71","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaci.2015.12.409","article-title":"Efficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophils","volume":"137","author":"Weinstein","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib72","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting B2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.024_bib73","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.11.024_bib74","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib76","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.11.024_bib77","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib78","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib79","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2019.11.024_bib80","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib81","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib82","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0091-6749(96)70123-9","article-title":"Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long term outcomes","volume":"98","author":"Stevenson","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1164\/ajrccm.165.1.2010080","article-title":"Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial","volume":"165","author":"Dahl\u00e9n","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.11.024_bib84","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jaip.2015.03.001","article-title":"Survey-defined patient experiences with aspirin-exacerbated respiratory disease","volume":"3","author":"Ta","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib85","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2011.3.1.3","article-title":"Aspirin-exacerbated respiratory disease: evaluation and management","volume":"3","author":"Lee","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2019.11.024_bib86","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib87","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"\u015awierczy\u0144ska-Kr\u0119pa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib88","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.11.024_bib90","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaip.2015.01.012","article-title":"Omalizumab in the treatment of aspirin-exacerbated respiratory disease","volume":"3","author":"Bergmann","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib91","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.11.024_bib92","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981930964X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221321981930964X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:22:43Z","timestamp":1761974563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221321981930964X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S221321981930964X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.11.024","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilic Asthma","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.11.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}